Yang R, Yang C, Hao Y
Institute of Hematology, CAMS & PUMC, Tianjin.
Zhonghua Zhong Liu Za Zhi. 1995 Sep;17(5):340-2.
K562/A02 is a Cell line with multi-drug resistance established in our laboratory bey long term induction with adriamycin. In this paper, reversal of MDR in K562/A02 cell line by tripiperaquine is reported. The cytotoxicity and intracellular concentration of daunorubicin (DNR) in K562/A02 were measured by MTT colorimetric assay and spectrofluorimetry. The results showed that the sensitivity of K562/A02 to DNR was greatly enhanced by tripiperaquine at 10 micrograms/ml, with an 11-fold increase in cytotoxic activity. The intracellular concentration of DNR in K562/A02 was significantly increased after coincubation with 20 mumol/L tripiperaquine for 3 hours. Our results suggest that tripiperaquine might be used in clinical trial to reverse MDR.
K562/A02是本实验室通过阿霉素长期诱导建立的多药耐药细胞系。本文报道了三哌喹对K562/A02细胞系多药耐药性的逆转作用。采用MTT比色法和荧光分光光度法测定了K562/A02细胞中柔红霉素（DNR）的细胞毒性和细胞内浓度。结果表明，10微克/毫升的三哌喹可显著增强K562/A02对DNR的敏感性，细胞毒性活性增加11倍。与20微摩尔/升三哌喹共孵育3小时后，K562/A02细胞内DNR浓度显著增加。我们的结果表明，三哌喹可能用于临床试验以逆转多药耐药性。
